MCID: PST011
MIFTS: 53

Pustulosis of Palm and Sole

Categories: Skin diseases

Aliases & Classifications for Pustulosis of Palm and Sole

MalaCards integrated aliases for Pustulosis of Palm and Sole:

Name: Pustulosis of Palm and Sole 12 15
Psoriasis 43 71
Pustular Psoriasis of the Palms and/or Soles 12
Acrodermatitis Continua of Hallopeau 71
Generalized Pustular Psoriasis 71
Pustulosis of Palms and Soles 71
Palmoplantar Pustulosis 12
Acropustulosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4398
MeSH 43 D011565
NCIt 49 C34888
SNOMED-CT 67 27520001
ICD10 32 L40.3
UMLS 71 C0030246 C0033860 C0343055 more

Summaries for Pustulosis of Palm and Sole

MalaCards based summary : Pustulosis of Palm and Sole, also known as psoriasis, is related to impetigo herpetiformis and psoriasis 14, pustular, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Pustulosis of Palm and Sole is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are hematopoietic system and immune system

Related Diseases for Pustulosis of Palm and Sole

Diseases related to Pustulosis of Palm and Sole via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1322)
# Related Disease Score Top Affiliating Genes
1 impetigo herpetiformis 33.1 IL36RN IL1RL2 CARD14
2 psoriasis 14, pustular 33.0 IL36RN AP1S3
3 pustular psoriasis 32.8 TNF IL36RN AP1S3
4 geographic tongue 32.8 IL36RN IL1RL2 CARD14
5 pustulosis palmaris et plantaris 32.4 TNF IL36RN CCR6 AP1S3
6 systemic onset juvenile idiopathic arthritis 32.3 TNF IL1RN
7 chickenpox 30.7 TNFRSF1B TNF CCR6
8 necrobiosis lipoidica 30.6 TNFRSF1B TNF
9 enthesopathy 30.6 TNFRSF1B TNF MRAP CCR6
10 nail disease 30.5 TNFRSF1B TNF IL17A CCR6
11 syphilis 30.5 MRAP IL17A CCR6
12 cutaneous candidiasis 30.5 IL17A CCR6
13 glossitis 30.5 TNF IL36RN IL1RL2
14 tenosynovitis 30.4 TNFRSF1B TNF MRAP
15 rheumatic disease 30.3 TNFRSF1B TNF IL1RN CCR6
16 lichen planus 30.3 TNF IL17A CXCL8
17 synovitis 30.3 TNF IL1RN CXCL8
18 rosacea 30.3 TNF CXCL8 CCR6
19 crohn's colitis 30.3 TNF CXCL8 CCR6
20 skin sarcoidosis 30.3 TNFRSF1B TNF
21 histoplasmosis 30.3 TNFRSF1B TNF CCR6
22 spondylitis 30.2 TNFRSF1B TNF IL1RN IL17A CCR6
23 acute generalized exanthematous pustulosis 30.2 IL36RN IL17A CXCL8
24 acquired immunodeficiency syndrome 30.1 TNFRSF1B TNF CCR6
25 ankylosis 30.1 TNFRSF1B TNF MRAP CCR6
26 nasopharyngitis 30.1 TNFRSF1B TNF IL17A
27 sarcoidosis 1 30.1 TNFRSF1B TNF MRAP IL1RN CCR6
28 allergic contact dermatitis 30.1 TNF IL17A CXCL8
29 childhood type dermatomyositis 30.0 TNFRSF1B TNF CCR6
30 bursitis 30.0 TNFRSF1B TNF MRAP
31 iridocyclitis 30.0 TNFRSF1B TNF MRAP IL17A
32 leukemia, acute monocytic 30.0 TNF SIGLEC5 CXCL8
33 iritis 30.0 TNFRSF1B TNF MRAP CCR6
34 meningitis 29.9 TNF IL17A CXCL8
35 acrodermatitis 29.9 TNFRSF1B IL36RN IL1RL2 CARD14 AP1S3
36 posterior uveitis 29.9 TNF MRAP CCR6
37 neurofibromatosis, type ii 29.9 TNF SIGLEC5 IL1RN CXCL8 CCR6
38 tendinitis 29.9 TNFRSF1B TNF MRAP
39 chlamydia 29.9 TNF IL17A CXCL8
40 dermatitis 29.9 TNF IL17A CXCL8 CCR6
41 osteomyelitis 29.9 TNF LPIN2 IL1RN CXCL8
42 posterior scleritis 29.9 TNF MRAP
43 leprosy 3 29.8 TNF IL17A CXCL8 CCR6
44 candidiasis 29.8 TNF IL17A CXCL8
45 retinal vasculitis 29.8 TNFRSF1B MRAP CCR6
46 pharyngitis 29.8 TNFRSF1B TNF IL1RN CXCL8
47 mycobacterium tuberculosis 1 29.8 TNFRSF1B TNF IL17A CCR6
48 blepharitis 29.8 TNF CXCL8 CCR6
49 spondyloarthropathy 1 29.8 TNFRSF1B TNF MRAP IL1RN IL17A CCR6
50 alopecia areata 29.8 TNF IL1RN IL17A

Graphical network of the top 20 diseases related to Pustulosis of Palm and Sole:



Diseases related to Pustulosis of Palm and Sole

Symptoms & Phenotypes for Pustulosis of Palm and Sole

UMLS symptoms related to Pustulosis of Palm and Sole:


pruritus, exanthema, psoriasiform rash

MGI Mouse Phenotypes related to Pustulosis of Palm and Sole:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 CCR6 GPRIN1 IL17A IL1RL2 IL1RN IL36RN
2 immune system MP:0005387 9.7 CARD14 CCR6 GPRIN1 IL17A IL1RL2 IL1RN
3 integument MP:0010771 9.23 CARD14 IL17A IL1RL2 IL1RN IL36RN PSTPIP2

Drugs & Therapeutics for Pustulosis of Palm and Sole

Drugs for Pustulosis of Palm and Sole (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 459)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
4
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
5
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5282493 5311052
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
9
carbamide peroxide Approved Phase 4 124-43-6
10 Orange Approved Phase 4
11 Strawberry Approved Phase 4
12 Artichoke Approved Phase 4
13
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
14 Brodalumab Approved, Investigational Phase 4 1174395-19-7
15
Adalimumab Approved Phase 4 331731-18-1 16219006
16
Certolizumab pegol Approved Phase 4 428863-50-7
17
Desoximetasone Approved Phase 4 382-67-2 5311067
18
Abatacept Approved Phase 4 332348-12-6 10237
19
Tofacitinib Approved, Investigational Phase 4 477600-75-2
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Mercaptopurine Approved Phase 4 50-44-2 667490
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
24 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
25
Ustekinumab Approved, Investigational Phase 4 815610-63-0
26
Metformin Approved Phase 4 657-24-9 4091 14219
27 Vedolizumab Approved Phase 4 943609-66-3
28
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
29
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
30
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
36
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
37 Retinol palmitate Phase 4
38 retinol Phase 4
39 Antiparasitic Agents Phase 4
40 Antimalarials Phase 4
41 Antiprotozoal Agents Phase 4
42 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
43 Tin Fluorides Phase 4
44 Immunoglobulin A Phase 4
45
Chondroitin Phase 4 9007-27-6 53477707
46 Halobetasol Phase 4
47 Clocortolone pivalate Phase 4
48 Olive Phase 4
49 Omega 3 Fatty Acid Phase 4
50 Citrate Phase 4

Interventional clinical trials:

(show top 50) (show all 1611)
# Name Status NCT ID Phase Drugs
1 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
4 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
5 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
6 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
7 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
9 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
10 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
11 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
13 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
14 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
15 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
16 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
17 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
18 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
19 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
20 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
21 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
22 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
23 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
24 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
25 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
26 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
27 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
28 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
29 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
30 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
31 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
32 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
33 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
34 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
35 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray
36 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
37 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
38 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
39 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
40 An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
41 A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis Completed NCT02274792 Phase 4 Etanercept
42 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
43 A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS Completed NCT02187172 Phase 4 Ustekinumab;Placebo
44 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast Completed NCT02749370 Phase 4 Etanercept
45 A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects. Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
46 An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis Completed NCT00437255 Phase 4 Clobetasol Propionate, 0.05%;Calcipotriene and betamethasone dipropionate ointment
47 A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis Completed NCT00436540 Phase 4 Clobetasol Propionate 0.05% Spray;Clobetasol Propionate 0.05% Foam
48 Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis Completed NCT01766440 Phase 4 Calcitriol 3 mcg/g ointment
49 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
50 A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Completed NCT03506477 Phase 4 Enstilar® foam;Vehicle foam

Search NIH Clinical Center for Pustulosis of Palm and Sole

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Cochrane evidence based reviews: psoriasis

Genetic Tests for Pustulosis of Palm and Sole

Anatomical Context for Pustulosis of Palm and Sole

MalaCards organs/tissues related to Pustulosis of Palm and Sole:

40
Skin, T Cells, Testes, Liver, Neutrophil, Endothelial, Bone

Publications for Pustulosis of Palm and Sole

Articles related to Pustulosis of Palm and Sole:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes. 61
31486084 2020
2
Bidirectional association between psoriasis and depression: Two longitudinal follow-up studies using a national sample cohort. 61
31733456 2020
3
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. 61
31425723 2020
4
Psoriasis causes as much disability as other major medical diseases. 61
31837740 2020
5
How It Works: The Immunology Underlying Phototherapy. 61
31753191 2020
6
Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review. 61
31150716 2020
7
Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis. 61
31400455 2020
8
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. 61
31734402 2020
9
The Science and (Lost) Art of Psoralen Plus UVA Phototherapy. 61
31753184 2020
10
Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. 61
31727784 2020
11
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective. 61
31727781 2020
12
Optimizing Narrowband UVB Phototherapy Regimens for Psoriasis. 61
31753182 2020
13
Management of pediatric plaque psoriasis using biologics. 61
31150699 2020
14
Bleeding erosions in a man with psoriasis. 61
31326941 2020
15
Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study. 61
31150706 2020
16
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. 61
31640431 2020
17
Psoriasis prevalence in the United States in a commercial insurance claims database: 2011-2017. 61
31708187 2020
18
Convallatoxin induces HaCaT cell necroptosis and ameliorates skin lesions in psoriasis-like mouse models. 61
31707343 2020
19
Melissa officinalis ssp. altissima extracts: A therapeutic approach targeting psoriasis in mice. 61
31476443 2020
20
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. 61
31703821 2020
21
JAAD Game Changers: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). 61
31394134 2020
22
A human embryonic stem cell-based in vitro model revealed that ultrafine carbon particles may cause skin inflammation and psoriasis. 61
31791492 2020
23
Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer. 61
31566114 2020
24
Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. 61
31163240 2020
25
Kan-Lu-Hsiao-Tu-Tan, a traditional Chinese medicine formula, inhibits human neutrophil activation and ameliorates imiquimod-induced psoriasis-like skin inflammation. 61
31539577 2020
26
Polypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis. 61
31843640 2019
27
A novel vehicle for the treatment of psoriasis. 61
31830367 2019
28
Imaging techniques in the diagnosis and monitoring of psoriasis. 61
31819765 2019
29
Epicardial fat: a new therapeutic target in psoriasis. 61
31808384 2019
30
[Psoriasis therapy in pregnancy : Consultation of pregnant patients]. 61
31218417 2019
31
Forrest III duodenal ulcers during treatment with adalimumab for psoriasis. 61
30663463 2019
32
Acute unilateral red eye in a patient with psoriasis. 61
30746729 2019
33
[Severity scores for childhood psoriasis: A systematic literature review]. 61
31060749 2019
34
Psychological and Sexual Consequences of Psoriasis Vulgaris on Patients and Their Partners. 61
31542353 2019
35
A case of concurrent psoriasis and ulcerative colitis with development of arthritis during adalimumab treatment. 61
31806587 2019
36
Keratoconus Could Be Associated With Psoriasis: Novel Findings From a Comparative Study. 61
31574049 2019
37
Current clinical issue of skin lesions in patients with inflammatory bowel disease. 61
30838512 2019
38
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. 61
31836320 2019
39
Real-world experiences of apremilast in clinics for Japanese patients with psoriasis. 61
31587350 2019
40
Gut microbiota dysbiosis in a cohort of patients with psoriasis. 61
30920647 2019
41
EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment. 61
31837587 2019
42
CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages. 61
31835080 2019
43
Aspects concerning patient adherence to anti-TNFα therapy in psoriasis: A decade of clinical experience. 61
31798720 2019
44
Psoriasis and liver fibrosis: an investigation using transient elastography in Tunisian patients with psoriasis. 61
31145808 2019
45
Exacerbation of systemic lupus erythematosus in a patient with concomitant chronic plaque psoriasis treated with ustekinumab. 61
31823905 2019
46
IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. 61
31793105 2019
47
Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab. 61
31260082 2019
48
Histopathologic findings characteristic of CARD14-associated papulosquamous eruption. 61
31849081 2019
49
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. 61
31399223 2019
50
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. 61
31493163 2019

Variations for Pustulosis of Palm and Sole

Expression for Pustulosis of Palm and Sole

Search GEO for disease gene expression data for Pustulosis of Palm and Sole.

Pathways for Pustulosis of Palm and Sole

Pathways related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A
2
Show member pathways
13.08 TNFRSF1B TNF IL1RN IL1RL2 IL17A CXCL8
3 12.29 TNFRSF1B TNF IL1RN IL17A
4
Show member pathways
11.89 TNFRSF1B TNF CXCL8 CCR6
5 11.64 TNF CXCL8 CARD14
6
Show member pathways
11.6 TNF IL36RN IL1RN IL1RL2 CXCL8
7 11.58 TNF IL17A CXCL8
8 11.51 TNFRSF1B TNF IL17A CXCL8
9 11.48 TNF IL17A CCR6
10 11.35 TNF IL1RN IL17A
11 10.79 TNF CXCL8
12 10.61 TNFRSF1B TNF IL1RN CXCL8

GO Terms for Pustulosis of Palm and Sole

Biological processes related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.72 TNFRSF1B TNF IL36RN IL1RN CXCL8
2 immune response GO:0006955 9.7 TNFRSF1B TNF IL36RN IL1RN IL17A CXCL8
3 tumor necrosis factor-mediated signaling pathway GO:0033209 9.63 TNFRSF1B TNF CARD14
4 positive regulation of JNK cascade GO:0046330 9.58 TNF IL36RN IL1RN
5 positive regulation of interleukin-6 production GO:0032755 9.56 TNF IL36RN IL1RN IL1RL2
6 neutrophil chemotaxis GO:0030593 9.54 IL36RN IL1RN CXCL8
7 inflammatory response GO:0006954 9.5 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A
8 embryonic digestive tract development GO:0048566 9.48 TNF CXCL8
9 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.43 TNFRSF1B TNF
10 cytokine-mediated signaling pathway GO:0019221 9.17 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A

Molecular functions related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.16 IL36RN IL1RN
2 cytokine activity GO:0005125 9.02 TNF IL36RN IL1RN IL17A CXCL8
3 interleukin-1 receptor antagonist activity GO:0005152 8.96 IL36RN IL1RN

Sources for Pustulosis of Palm and Sole

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....